An Open-Label, Multi-Center Study of LJPC‑501 in Pediatric Patients Who Remain Hypotensive Despite Receiving Fluid Therapy and Vasopressor Therapy

Trial Profile

An Open-Label, Multi-Center Study of LJPC‑501 in Pediatric Patients Who Remain Hypotensive Despite Receiving Fluid Therapy and Vasopressor Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs LJPC 501 (Primary)
  • Indications Hypotension
  • Focus Therapeutic Use
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 21 Feb 2018 According to a La Jolla Pharmaceutical Company media release, the first pediatric patient has been treated in this trial.
    • 16 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top